FDA Expands BioMarin's Palynziq Approval to Adolescents with PKU
BMRN sits 17% above its 52-week low of $50.76.
Summary
The U.S. Food and Drug Administration (FDA) has approved BioMarin's Palynziq (pegvaliase-pqpz) for adolescents aged 12 and older with Phenylketonuria (PKU). This label expansion is a significant positive development, as it broadens the addressable patient population for an existing key drug. The approval is expected to increase Palynziq's market opportunity and contribute to BioMarin's revenue growth. This news is new information and was not previously disclosed in recent SEC filings or news, providing a fresh catalyst for the stock.
At the time of this announcement, BMRN was trading at $59.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $50.76 to $73.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.